
|Videos|September 9, 2021
Should anti-VEGF agents be used to treat patients with NPDR?
Author(s)OT Staff Reports
Jennifer Sun, MD, MPH, explores the question of whether ophthalmologists should be using anti-VEGF agents to treat patients with nonproliferative diabetic retinopathy (NPDR).
Advertisement
Jennifer Sun, MD, MPH, associate professor of Ophthalmology, Harvard Medical School; chief at the Center for Clinical Eye Research and Trials, Joslin Diabetes Center, explores the question of whether ophthalmologists should be using anti-VEGF agents to treat patients with nonproliferative diabetic retinopathy (NPDR).
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
MacTel masquerades: How to spot what others miss
2
Preclinical study explores contact lens–based neuromodulation for depression
3
QA102 data suggest signal in intermediate dry AMD, but insignificant drusen volume change
4
Avacincaptad pegol analysis links GA treatment to preserved driving vision
5























